<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897115</url>
  </required_header>
  <id_info>
    <org_study_id>W15-679</org_study_id>
    <secondary_id>2015-005398-18</secondary_id>
    <nct_id>NCT02897115</nct_id>
  </id_info>
  <brief_title>A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment</brief_title>
  <acronym>STRIKE</acronym>
  <official_title>STRIKE - Treating Patients With Early Axial Spondyloarthritis to Target - a 1 Year Randomized Controlled Study Taking an Intense Treatment Approach Versus Routine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Improvement by Movement GmbH, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IST GmbH, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study comparing a treat-to-target (T2T) intense treatment approach in participants with
      axial spondyloarthritis (axSpA) with routine treatment (Standard of Care (SOC)) concerning a
      reduction in disease activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2016</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">December 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease</measure>
    <time_frame>At Week 32</time_frame>
    <description>ASDAS inactive disease is defined as ASDAS &lt; 1.3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease state</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This accounts for participants with ASDAS &lt;1.3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving ASDAS major improvement</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count (66 joints)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>An assessment of 66 joints will be done by physical examination at the designated study visits. Joint swelling will be classified as present (1), absent (0), replaced (9), or no assessment (NA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath AS Disease Activity Index</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This is used to measure disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving ASAS 40</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>It is defined as improvement of &gt;= 40% in ASAS index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This is used to assess the effect of participant's axial spondyloarthritis on their ability to work and perform regular activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte sedimentation rate</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>ESR will be evaluated at the site and expressed in mm/hg (1st hour).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) high disease activity</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This accounts for participants with ASDAS &gt;= 2.1 to &lt; 3.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath Ankylosing Spondylitis Functional Index (BASFI) Numerical Rating Scale (NRS) score</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This is used to assess function. The score ranges from 0 (easy to perform an activity) to 10 (impossible to perform an activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life-5 Dimensions (EQ-5D) Questionnaire</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The EQ-5D is an international, standardized, generic instrument for describing and valuing health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician's Global Assessment of Disease Activity</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>NRS will be used to assess Physician's Global Assessment of Disease Activity. The left end of the NRS (0) signifies the absence of symptoms and the right end (10) signifies maximum activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving ASDAS clinically important improvement</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Dactylitis count (0 - 20)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>Evaluation for dactylitis will be conducted at the designated study visits to assess the presence or absence of dactylitis in all 20 of the subjects' digits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tender Joint Count (68 joints)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>An assessment of 68 joints will be done by physical examination at the designated study visits. Joint pain/tenderness will be classified as present (1), absent (0), replaced (9), or no assessment (NA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ASDAS</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving BASDAI 50 response</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This accounts for participants achieving 50% improvement in BASDAI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving ASAS 20</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>It is defined as improvement of &gt;= 20% in ASAS index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) very high disease activity</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This accounts for participants with ASDAS &gt;= 3.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) moderate disease activity</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This accounts for participants with ASDAS &gt;= 1.3 to &lt; 2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This is used to asses overall functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior Uveitis</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This is assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Global Assessment of Disease Activity</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>NRS will be used to assess Patient's Global Assessment of Disease Activity. The left end of the NRS (0) signifies the absence of symptoms and the right end (10) signifies maximum activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The MASES evaluation will be conducted at the designated study visits to assess the presence or absence of enthesitis at 13 different sites, noting the subjects' responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Global Assessment of Pain</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>NRS will be used to assess Patient's Global Assessment of Pain. The left end of the NRS (0) signifies the absence of symptoms and the right end (10) signifies maximum activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Testing for CRP will be performed on specimens collected at the designated study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS partial remission</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>It indicates absolute score of &lt; 2 units for each of the domains listed in the criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This accounts for participants with ASDAS &lt;2.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berlin magnetic resonance imaging score</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This is used to assess active inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Target to Treat (T2T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depending on their disease activity, participants' basic NSAID therapy (at full recommended dose) will be changed after 4 weeks to another NSAID at its full recommended dose. After another 4 weeks, if applicable based on their disease activity, participants will receive Adalimumab in combination with their NSAID therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive treatment as prescribed by their physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Administered subcutaneously for a maximum of 48 weeks, depending on participants' disease activity observed.</description>
    <arm_group_label>Target to Treat (T2T)</arm_group_label>
    <other_name>Humira</other_name>
    <other_name>ABT-D2E7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care (SOC)</intervention_name>
    <description>Treatment according to participants' physicians' routine practice (local SOC).</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <other_name>Routine practice</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent before start of study-related assessments or
             procedures

          -  Diagnosis of axSpA (either ankylosing spondylitis or non-radiographic axSpA) and
             fulfilling the ASAS classification criteria for axSpA

          -  Participants aged &gt;= 18 years

          -  Disease duration &lt; 5 years

          -  Participants must have a Baseline disease activity as defined by an ASDAS &gt;= 2.1 or a
             BASDAI &gt;= 4

          -  NSAID-naive or not treated with the maximal recommended NSAID dose during the last 2
             weeks prior to the Baseline visit

          -  Participants must never have failed a NSAID taken at maximal recommended dose for 2
             weeks or more.

        Exclusion Criteria:

          -  Contraindications for NSAIDs or Tumor Necrosis Factor (TNF) blocker according to local
             labeling

          -  If entering the study on concomitant NSAIDs, participants taking the maximal
             recommended dose during the last 2 weeks prior to the Baseline Visit or have failed or
             developed intolerance to a NSAID taken at maximal recommended dose for 2 weeks or more
             at any time

          -  Prior exposure to any anti-TNF therapy; any biologic therapy with a potential
             therapeutic impact on SpA, or participant has been treated with any investigational
             drug of chemical or biologic nature within a minimum of 30 days or five half-lives
             (whichever is longer) of the drug prior to the Baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatologische Gemeinschafts</name>
      <address>
        <city>Bad Neuenahr</city>
        <zip>53474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpr</name>
      <address>
        <city>Berlin</city>
        <zip>12161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fuer Rheumatologie</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite-Univ Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Rheumat</name>
      <address>
        <city>Burghausen</city>
        <zip>84489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRI GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklin</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburger Rheuma I</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Kliniken des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMO MD GmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis An der Hase</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Planegg</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftsklinikum Saar GmbH</name>
      <address>
        <city>Puettlingen</city>
        <zip>66346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumaforschung Studienambulan</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Praxis</name>
      <address>
        <city>Rendsburg</city>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Josef</name>
      <address>
        <city>Wuppertal</city>
        <zip>42105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axial Spondyloarthritis</keyword>
  <keyword>Humira</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

